{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:22:01Z","timestamp":1784719321750,"version":"3.55.0"},"reference-count":93,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>SARS-CoV-2\/Coronavirus 2019 (COVID-19) is responsible for the pandemic, which started in December 2019. In addition to the typical respiratory symptoms, this virus also causes other severe complications, including neurological ones. In diagnostics, serological and polymerase chain reaction tests are useful not only in detecting past infections but can also predict the response to vaccination. It is now believed that an immune mechanism rather than direct viral neuroinvasion is responsible for neurological symptoms. For this reason, it is important to assess the presence of antibodies not only in the serum but also in the cerebrospinal fluid (CSF), especially in the case of neuro-COVID. A particular group of patients are people with multiple sclerosis (MS) whose disease-modifying drugs weaken the immune system and lead to an unpredictable serological response to SARS-CoV-2 infection. Based on available data, the article summarizes the current serological information concerning COVID-19 in CSF in patients with severe neurological complications and in those with MS.<\/jats:p>","DOI":"10.3390\/ijms22115894","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T05:53:38Z","timestamp":1622440418000},"page":"5894","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Significance of COVID-19 Immunological Status in Severe Neurological Complications and Multiple Sclerosis\u2014A Literature Review"],"prefix":"10.3390","volume":"22","author":[{"given":"Joanna","family":"Kulikowska","sequence":"first","affiliation":[{"name":"Department of Neurology, Medical University of Bialystok, 15-276 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9889-3585","authenticated-orcid":false,"given":"Agnieszka","family":"Kulczy\u0144ska-Przybik","sequence":"additional","affiliation":[{"name":"Department of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4075-8479","authenticated-orcid":false,"given":"Barbara","family":"Mroczko","sequence":"additional","affiliation":[{"name":"Department of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Ku\u0142akowska","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Bialystok, 15-276 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","unstructured":"(2021, April 30). Coronavirus Update (Live): 102,061,812 Cases and 2,201,477 Deaths from COVID-19 Virus Pandemic-Worldometer. Available online: https:\/\/www.worldometers.info\/coronavirus\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/HAB-200429","article-title":"COVID-19: Significance of antibodies","volume":"28","author":"Assadiasl","year":"2020","journal-title":"Hum. Antibodies"},{"key":"ref_4","first-page":"424432","article-title":"Coronavirus infections and immune responses","volume":"92","author":"Li","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nrmicro3143","article-title":"A decade after SARS: Strategies for controlling emerging coronaviruses","volume":"11","author":"Graham","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_6","unstructured":"Alhazzani, W., M\u00f8ller, M.H., Arabi, Y.M., Loeb, M., Gong, M.N., and Fan, E. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., and Gu, X. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet.","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Bhatt, P.J., Shiau, S., Brunetti, L., Xie, Y., Solanki, K., Khalid, S., Mohayya, S., Au, P.H., Pham, C., and Uprety, P. (2020). Risk Factors and Outcomes of Hospitalized Patients with Severe Coronavirus Disease 2019 (COVID-19) and Secondary Bloodstream Infections: A Multicenter Case-Control Study. Clin. Infect Dis.","DOI":"10.1093\/cid\/ciaa1748"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wu, C., Chen, X., Cai, Y., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., and Zhang, Y. (2020). Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med.","DOI":"10.1001\/jamainternmed.2020.0994"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-19808-4","article-title":"SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_11","unstructured":"(2020). Diagnosis and treatment plan of Corona Virus Disease 2019 (tentative sixth edition). Glob. Health J."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., and Li, J. (2020). Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis.","DOI":"10.1101\/2020.03.02.20030189"},{"key":"ref_13","unstructured":"Zhang, B., Zhou, X., Zhu, C., Song, Y., Feng, F., Qiu, Y., Feng, J., Jia, Q., Song, Q., and Zhu, B. (2020). Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1007\/s10072-020-04575-3","article-title":"Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: Understanding the neurological manifestations in COVID-19 patients","volume":"41","author":"Yachou","year":"2020","journal-title":"Neurol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s00415-020-09929-7","article-title":"Understanding the neurotropic characteristics of SARS-CoV-2: From neurological manifestations of COVID-19 to potential neurotropic mechanisms","volume":"267","author":"Zhou","year":"2020","journal-title":"J. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijid.2020.03.062","article-title":"A first case of meningitis\/encephalitis associated with SARS-Coronavirus-2","volume":"94","author":"Moriguchi","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1212\/NXI.0000000000000893","article-title":"Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome Studies in 8 stuporous and comatose patients","volume":"7","author":"Alexopoulos","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41577-020-00458-y","article-title":"Do cross-reactive antibodies cause neuropathology in COVID-19?","volume":"20","author":"Kreye","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Capasso, N., Palladino, R., Montella, E., Pennino, F., Lanzillo, R., Carotenuto, A., Petracca, M., Iodice, R., Iovino, A., and Aruta, F. (2020). Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg. J. Clin. Med., 9.","DOI":"10.3390\/jcm9124066"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jiph.2020.07.001","article-title":"Immune response in COVID-19: A review","volume":"13","author":"Chowdhury","year":"2020","journal-title":"J. Infect. Public Health"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Melenotte, C., Silvin, A., Goubet, A.G., Lahmar, I., Dubuisson, A., Zumla, A., Raoult, D., Merad, M., Gachot, B., and H\u00e9non, C. (2020). Immune responses during COVID-19 infection. Oncoimmunology, 9.","DOI":"10.1080\/2162402X.2020.1807836"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Zarrilli, G., Angerilli, V., Businello, G., Sbaraglia, M., Traverso, G., Fortarezza, F., Rizzo, S., Gaspari, M.D., Basso, C., and Calabrese, F. (2021). The Immunopathological and Histological Landscape of COVID-19-Mediated Lung Injury. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020974"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"915","DOI":"10.20452\/pamw.15658","article-title":"Management of SARS-CoV-2 infection: Recommendations of the polish association of epidemiologists and infectiologists. Annex no. 2 as of October 13, 2020","volume":"130","author":"Flisiak","year":"2020","journal-title":"Polish Arch. Intern Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Wong, N.A., and Saier, M.H. (2021). The SARS-Coronavirus Infection Cycle: A Survey of Viral Membrane Proteins, Their Functional Interactions and Pathogenesis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22031308"},{"key":"ref_25","first-page":"1","article-title":"Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study","volume":"5","author":"Tan","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Maggi, E., Walter Canonica, G., and Moretta, L. (2020). COVID-19: Unanswered questions on immune response and pathogenesis. J. Allergy Clin. Immunol.","DOI":"10.1016\/j.jaci.2020.05.001"},{"key":"ref_28","unstructured":"(2021, January 31). WIES\u0141AW WIKTOR J\u0118DRZEJCZAK: Limfohistiocytoza Hemofagocytarna\u2013Rzadko Rozpoznawany Uleczalny Stan Bezpo\u015bredniego Zagro\u017cenia \u017bycia Wyst\u0119puj\u0105cy R\u00f3wnie\u017c u Doros\u0142ych. Available online: http:\/\/pthit.pl\/Acta_Haematologica_Polonica,Choroby_histiocytow_Cytokiny_Wirus_Epsteina_Barr,406.html."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Tomasiewicz, K., Piekarska, A., Stempkowska-Rejek, J., Serafi\u0144ska, S., Gawkowska, A., Parczewski, M., Ni\u015bcigorska-Olsen, J., \u0141api\u0144ski, T.W., Zar\u0119bska-Michaluk, D., and Kowalska, J.D. (2020). Tocilizumab for patients with severe COVID-19: A retrospective, multi-centre study. Expert Rev. Anti Infect. Ther., 19.","DOI":"10.1080\/14787210.2020.1800453"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1136\/bmj.m2516","article-title":"Diagnostic accuracy of serological tests for covid-19: Systematic review and meta-analysis","volume":"370","author":"Bastos","year":"2020","journal-title":"BMJ"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5694\/mja2.50766","article-title":"Serological tests for COVID-19","volume":"213","author":"Bond","year":"2020","journal-title":"Med. J. Aust."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"McAndrews, K.M., Dowlatshahi, D.P., Dai, J., Becker, L.M., Hensel, J., Snowden, L.M., Leveille, J.M., Brunner, M.R., Holden, K.W., and Hopkins, N.S. (2020). Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight, 5.","DOI":"10.1172\/jci.insight.142386"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-19943-y","article-title":"Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19","volume":"11","author":"Li","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cca.2020.04.026","article-title":"IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study","volume":"507","author":"Padoan","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_35","first-page":"10208","article-title":"Seropositivity rate and diagnostic accuracy of serological tests in 2019-nCoV cases: A pooled analysis of individual studies","volume":"24","author":"Guo","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_36","unstructured":"(2021, January 31). Diagnostic Performance of COVID-19 Serology Assays-PubMed. Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/32342927\/."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Wan, Y., Shang, J., Sun, S., Tai, W., Chen, J., Geng, Q., He, L., Chen, Y., Wu, J., and Shi, Z. (2019). Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. J. Virol., 94.","DOI":"10.1128\/JVI.02015-19"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Song, E., Zhang, C., Israelow, B., Lu-Culligan, A., Prado, A.V., Skriabine, S., Lu, P., Weizman, O.E., Liu, F., and Dai, Y. (2021). Neuroinvasion of SARS-CoV-2 in human and mouse brain. J. Exp. Med., 218.","DOI":"10.1084\/jem.20202135"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"105131","DOI":"10.1016\/j.nbd.2020.105131","article-title":"The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood\u2013brain barrier","volume":"146","author":"Buzhdygan","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1136\/jnnp-2020-323522","article-title":"Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke","volume":"91","author":"Ghosh","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"117090","DOI":"10.1016\/j.jns.2020.117090","article-title":"Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms","volume":"418","author":"Neumann","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S2666-5247(20)30066-5","article-title":"Systematic SARS-CoV-2 screening in cerebrospinal fluid during the COVID-19 pandemic","volume":"1","author":"Destras","year":"2020","journal-title":"Lancet Microbe"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1007\/s00415-020-09996-w","article-title":"First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease","volume":"267","author":"Domingues","year":"2020","journal-title":"J. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1007\/s00415-020-09975-1","article-title":"COVID-19 encephalopathy: Detection of antibodies against SARS-CoV-2 in CSF","volume":"267","author":"Andriuta","year":"2020","journal-title":"J. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Franke, C., Ferse, C., Kreye, J., Reincke, S.M., Sanchez-Sendin, E., Rocco, A., Steinbrenner, M., Angermair, S., Treskatsch, S., and Zickler, D. (2021). High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav. Immun.","DOI":"10.1101\/2020.07.01.20143214"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"102783","DOI":"10.1016\/j.msard.2021.102783","article-title":"Para-infectious anti-GD2\/GD3 IgM myelitis during the Covid-19 pandemic: Case report and literature review","volume":"49","author":"Barriuso","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jocn.2020.07.074","article-title":"Acute myelitis and SARS-CoV-2 infection. A new etiology of myelitis?","volume":"80","year":"2020","journal-title":"J. Clin. Neurosci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1474-4422(18)30244-8","article-title":"Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: A prospective observational study and retrospective analysis","volume":"17","author":"Armangue","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/WCO.0000000000000445","article-title":"Postviral autoimmune encephalitis: Manifestations in children and adults","volume":"30","year":"2017","journal-title":"Curr. Opin. Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1093\/brain\/awx177","article-title":"Encephalitis lethargica: 100 years after the epidemic","volume":"140","author":"Hoffman","year":"2017","journal-title":"Brain"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1474-4422(20)30308-2","article-title":"Neuropathology of patients with COVID-19 in Germany: A post-mortem case series","volume":"19","author":"Matschke","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Tuma, R.L., Guedes, B.F., Carra, R., Iepsen, B., Rodrigues, J., Camelo-Filho, A.E., Kubota, G., Ferrari, M., Studart-Neto, A., and Oku, M.H. (2021). Clinical, cerebrospinal fluid, and neuroimaging findings in COVID-19 encephalopathy: A case series. Neurol. Sci., 42.","DOI":"10.1007\/s10072-020-04946-w"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Farhadian, S., Glick, L.R., Vogels, C.B.F., Thomas, J., Chiarella, J., Casanovas-Massana, A., Zhou, J., Odio, C., Vijayakumar, P., and Geng, B. (2020). Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19. BMC Neurol., 20.","DOI":"10.1186\/s12883-020-01812-2"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijid.2020.10.044","article-title":"Cerebrospinal fluid findings in neurological diseases associated with COVID-19 and insights into mechanisms of disease development","volume":"102","author":"Gomes","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_56","first-page":"1","article-title":"Meningoencephalitis associated with COVID-19: A systematic review","volume":"1","author":"Mondal","year":"2020","journal-title":"J. Neurovirol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbi.2020.04.017","article-title":"Encephalitis as a clinical manifestation of COVID-19","volume":"88","author":"Ye","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.bbi.2020.05.054","article-title":"Anti-NMDA receptor encephalitis in a psychiatric Covid-19 patient: A case report","volume":"87","author":"Panariello","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.seizure.2020.07.006","article-title":"Anti-NMDA receptor encephalitis presenting as new onset refractory status epilepticus in COVID-19","volume":"81","author":"Monti","year":"2020","journal-title":"Seizure"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5811\/cpcem.2020.5.47937","article-title":"A Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection","volume":"4","author":"Sarma","year":"2020","journal-title":"Clin. Pract. Cases Emerg. Med."},{"key":"ref_61","unstructured":"(2021, February 06). Immunopathogenesis of Acute Transverse Myelitis: Current Opinion in Neurology. Available online: https:\/\/journals.lww.com\/co-neurology\/Citation\/2002\/06000\/Immunopathogenesis_of_acute_transverse_myelitis.19.aspx."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1007\/s00415-020-09934-w","article-title":"Acute transverse myelitis after COVID-19 pneumonia","volume":"267","author":"Munz","year":"2020","journal-title":"J. Neurol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.radcr.2020.06.001","article-title":"Acute myelitis as a neurological complication of Covid-19: A case report and MRI findings","volume":"15","author":"AlKetbi","year":"2020","journal-title":"Radiol Case Reports."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Abu-Rumeileh, S., Abdelhak, A., Foschi, M., Tumani, H., and Otto, M. (2020). Guillain\u2013Barr\u00e9 syndrome spectrum associated with COVID-19: An up-to-date systematic review of 73 cases. J. Neurol.","DOI":"10.1007\/s00415-020-10124-x"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"100203","DOI":"10.1016\/j.bbih.2021.100203","article-title":"GM1 Ganglioside Antibody and COVID-19 related Guillain Barre Syndrome\u2014A Case Report, Systemic Review and Implication for Vaccine Development","volume":"12","author":"Dufour","year":"2021","journal-title":"Brain, Behav. Immun. Health"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.nrl.2020.07.004","article-title":"Relation between COVID-19 and Guillain-Barr\u00e9 syndrome in adults. Systematic review","volume":"35","year":"2020","journal-title":"Neurologia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/jns.12419","article-title":"Guillain-Barr\u00e9syndrome associated with SARS-CoV-2 infection: A systematic review and individual participant data meta-analysis","volume":"25","author":"Hasan","year":"2020","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Llorente Ayuso, L., Torres Rubio, P., Beijinho do Ros\u00e1rio, R.F., Giganto Arroyo, M.L., and Sierra-Hidalgo, F. (2020). Bickerstaff encephalitis after COVID-19. J. Neurol.","DOI":"10.1007\/s00415-020-10201-1"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1136\/jnnp-2020-323816","article-title":"Postinfectious brainstem encephalitis associated with SARS-CoV-2","volume":"91","author":"Khoo","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"102174","DOI":"10.1016\/j.msard.2020.102174","article-title":"The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic","volume":"43","author":"Baker","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1212\/WNL.32.3.292","article-title":"Antibodies to coronaviruses OC43 and 229E in multiple sclerosis patients","volume":"32","author":"Salmi","year":"1982","journal-title":"Neurology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","article-title":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","volume":"29","author":"Comi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1016\/j.msard.2020.102476","article-title":"Normal antibody response after COVID-19 during treatment with cladribine","volume":"46","author":"Celius","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_75","first-page":"3","article-title":"COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: A monocentric experience","volume":"1","author":"Preziosa","year":"2020","journal-title":"J. Neurol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"102775","DOI":"10.1016\/j.msard.2021.102775","article-title":"COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?","volume":"49","author":"Gelibter","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_77","first-page":"e1999","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study","volume":"95","author":"Calkwood","year":"2020","journal-title":"Neurology."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"102323","DOI":"10.1016\/j.msard.2020.102323","article-title":"Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report","volume":"44","author":"Lucchini","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4049\/jimmunol.1601775","article-title":"Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems","volume":"199","author":"Boyaka","year":"2017","journal-title":"J. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Maillart, E., Papeix, C., Lubetzki, C., Roux, T., Pourcher, V., and Louapre, C. (2020). Beyond COVID-19: DO MS\/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?. Mult. Scler. Relat. Disord., 46.","DOI":"10.1016\/j.msard.2020.102482"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"102341","DOI":"10.1016\/j.msard.2020.102341","article-title":"Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab","volume":"44","author":"Thornton","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"102315","DOI":"10.1016\/j.msard.2020.102315","article-title":"Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia","volume":"44","author":"Conte","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Zabalza, A., C\u00e1rdenas-Robledo, S., Tagliani, P., Arrambide, G., Otero-Romero, S., Carbonell-Mirabent, P., Rodriguez-Barranco, M., Rodr\u00edguez-Acevedo, B., Restrepo Vera, J.L., and Resina-Salles, M. (2020). COVID-19 in multiple sclerosis patients: Susceptibility, severity risk factors and serological response. Eur. J. Neurol.","DOI":"10.1111\/ene.14690"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"27","DOI":"10.17925\/ENR.2020.15.1.27","article-title":"Ofatumumab\u2014A Potential Subcutaneous B-cell Therapy for Relapsing Multiple Sclerosis","volume":"15","author":"Milo","year":"2020","journal-title":"Eur. Neurol. Rev."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Flores-Gonzalez, R.E., Hernandez, J., Tornes, L., Rammohan, K., and Delgado, S. (2021). Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab. Mult. Scler. Relat. Disord., 49.","DOI":"10.1016\/j.msard.2021.102777"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40263-015-0299-y","article-title":"Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis","volume":"30","author":"Chan","year":"2016","journal-title":"CNS Drugs"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"117011","DOI":"10.1016\/j.jns.2020.117011","article-title":"Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide","volume":"416","author":"Luca","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1212\/WNL.0b013e31829e6fbf","article-title":"Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis","volume":"81","author":"Freedman","year":"2013","journal-title":"Neurology"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Okba, N.M.A., Muller, M.A., and Li, W. (2020). SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv.","DOI":"10.1101\/2020.03.18.20038059"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cell.2020.08.028","article-title":"Effects of COVID-19 on the Nervous System","volume":"183","author":"Iadecola","year":"2020","journal-title":"Cell"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1212\/NXI.0000000000000761","article-title":"COVID-19 and MS disease-modifying therapies","volume":"7","author":"Berger","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical Characteristics and Outcomes in Patients with Coronavirus Disease 2019 and Multiple Sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.13495","article-title":"COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases","volume":"202","author":"Baker","year":"2020","journal-title":"Clin. Exp Immunol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/11\/5894\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:09:17Z","timestamp":1760162957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/11\/5894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":93,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["ijms22115894"],"URL":"https:\/\/doi.org\/10.3390\/ijms22115894","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,31]]}}}